The treatment standard for HL is chemotherapy with or without radiation therapy. Identified drawbacks of these treatment options are related to their toxicity and limited efficacy in some patients. The authors report on new cytotoxic agents that are being investigated for use in the treatment of HL and emphasize the need for more patients to participate in clinical trials.